Biopharmaceutical company Cardiome Pharma announced that BRINAVESS (vernakalant intravenous) has been approved in South Africa for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Approval was granted by the Medicines Control Council (MCC), which oversees the regulation of medicines in South Africa.

Cardiome is pleased to have received this approval in South Africa and is dedicated to partnering BRINAVESS in this important pharmaceutical market as it continues focusing direct sales efforts on key countries in Europe.

One of the largest countries in Africa in terms of established pharmaceutical markets, South Africa saw total pharmaceutical sales reaching $3.7 billion USD in 2011, according to research conducted by IMS Health.

A biopharmaceutical company, Cardiome is engaged in the discovery, development, and commercialization of new therapies to improve the health of patients across the globe. BRINAVESS is currently the company’s only marketed product and has been approved in Europe and other territories.

For more information about Cardiome, visit www.cardiome.com

Let us hear your thoughts below: